Drug Development

Hematologist Jason Gotlib wanted more effective treatments for patients with systemic mastocytosis. His research has led to the approval of two new treatments by the Food and Drug Administration.

Researchers have identified a mechanism underlying fragmented sleep with older age, paving the way for potential drug therapies.

Stanford Medicine investigators and their collaborators have designed a compound that’s uniquely capable of blocking excessive mucus secretion — a hallmark of several serious respiratory disorders.

Stanford Medicine scientists explain what we know, and what we don’t know, about living with COVID-19 two years after the World Health Organization declared a pandemic.

The structure of a critical cellular-signaling molecule has finally been discovered by Stanford researchers. The finding may lead to new therapies.

Tuberculosis lesions in the lungs have high levels of proteins that suppress the immune system. Cancer drugs that target these proteins could be used to fight the bacterial infection.

A new study has identified a way that the immune system shoots down its own cells when their anti-viral activity threatens to become friendly fire. The finding could pave the way to new treatments for autoimmune diseases.

Deerfield Management, a health care investment firm, has committed up to $130 million to support innovative translational research at Stanford.

In the final installment of The Pandemic Puzzle: Lessons from COVID-19, leaders in government, academia, health care and business said biomedical and digital health advances of the last few years will help combat future health crises.

New medications help many people with inflammatory conditions and may ease severe COVID-19, but they carry risks.

Stanford pediatricians helped conduct clinical trials of COVID-19 vaccines for children. Data from the study will be submitted to the Food and Drug Administration for consideration.